系统性红斑狼疮肾脏复发的预测因素:四项贝利尤单抗III期临床试验的事后分析
该事后分析利用四项贝利尤单抗治疗SLE的III期试验数据,评估活动性肾外疾病患者肾脏复发的预测因素。3225例参与者中192例发生至少一次肾脏复发,中位首次复发时间为197天。基线肾脏受累史、低白蛋白血症、蛋白尿和低C3水平是肾脏复发的稳健决定因素。
要点
- 当前或既往肾脏受累、基线低白蛋白血症、蛋白尿和低C3水平是肾脏复发的稳健预测因素。
- 抗dsDNA阳性与肾脏复发风险升高相关,但校正后此关联减弱。
- 抗Sm阳性仅在安慰剂组与肾脏复发相关,抗核糖体P阳性仅在贝利尤单抗组与肾脏复发相关。
核心结论
- 肾脏受累史、基线高蛋白尿、低白蛋白血症和C3消耗是即将发生肾脏复发的稳健决定因素。
- 除抗dsDNA外,抗Sm和抗核糖体P蛋白抗体阳性可能在SLE肾脏监测中有价值。
研究设计与样本
- 研究为四项贝利尤单抗治疗SLE的III期临床试验(BLISS-52、BLISS-76、BLISS-NEA、BLISS-SC)的事后分析。
- 患者在接受标准治疗基础上被分配至贝利尤单抗组或安慰剂组。
- 采用比例风险回归分析,评估至第52-76周肾脏复发的预测因素。
主要发现
- 3225例参与者中,192例在随访期间发生至少一次肾脏复发,首次复发的中位时间为197天。
- 基线当前或既往肾脏受累的HR为15.4(95%CI 8.3-28.2,P<0.001),低血清白蛋白水平的HR为0.9(95%CI 0.8-0.9,P<0.001),蛋白尿的HR为1.6(95%CI 1.5-1.7,P<0.001),低C3水平的HR为2.9(95%CI 2.1-4.1,P<0.001)。
- 抗dsDNA阳性与肾脏复发风险升高相关(HR 2.1,95%CI 1.4-3.2,P<0.001),但校正后此关联减弱。
- 抗Sm阳性与肾脏复发相关见于安慰剂组(HR 3.7,95%CI 2.0-6.9,P<0.001),但未见于贝利尤单抗组。
- 抗核糖体P阳性与肾脏复发相关仅见于贝利尤单抗组(HR 2.8,95%CI 1.5-5.0,P=0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to identify predictors of renal flares in patients with SLE treated for active extra-renal disease. METHODS: Data from four clinical trials of belimumab in SLE (BLISS-52, NCT00424476; BLISS-76, NCT00410384; BLISS-NEA, NCT01345253; BLISS-SC, NCT01484496) were used. Patients were assigned to belimumab or placebo on top of standard therapy. We investigated the performance of predictors of renal flares through weeks 52-76 using proportional hazards regression analysis. RESULTS: Of 3225 participants, 192 developed at least one renal flare during follow-up, with the first occurring after a median time of 197 days. Current/former renal involvement [hazards ratio (HR): 15.4; 95% CI: 8.3-28.2; P < 0.001], low serum albumin levels (HR 0.9; 95% CI: 0.8-0.9; P < 0.001), proteinuria (HR: 1.6; 95% CI: 1.5-1.7; P < 0.001), and low C3 levels (HR: 2.9; 95% CI: 2.1-4.1; P < 0.001) at baseline appeared robust determinants of impending renal flares. Anti-dsDNA positivity yielded an increased hazard for renal flares (HR: 2.1; 95% CI: 1.4-3.2; P < 0.001), which attenuated after adjustments. Anti-Sm positivity was associated with renal flares in the placebo (HR: 3.7; 95% CI: 2.0-6.9; P < 0.001) but not in the belimumab subgroup, whereas anti-ribosomal P positivity was associated with renal flares in the belimumab subgroup only (HR: 2.8; 95% CI: 1.5-5.0; P = 0.001). CONCLUSION: A history of renal involvement, high baseline proteinuria, hypoalbuminaemia, and C3 consumption were robust determinants of impending renal flares. In addition to anti-dsDNA, anti-Sm and anti-ribosomal P protein antibody positivity may have value in surveillance of renal SLE.
引用
- Jägerback S, Gomez A, Parodis I, et al. Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab. Rheumatology (Oxford). 2025. PMID: 38216728. doi:10.1093/rheumatology/keae023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。